Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Verizon Communications Inc (VZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Verizon Communications IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Verizon Communications Inc vs Zimmer Biomet Holdings Inc — how do they compare? Verizon Communications Inc trades at $41.21 (market cap $192.57B), while Zimmer Biomet Holdings Inc trades at $89.01 (market cap $16.95B). The key difference: Verizon Communications Inc is far larger — about 11.4× Zimmer Biomet Holdings Inc's market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Verizon Communications Inc for 109 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

VZZBH
Market Cap
$192.57B$16.95B
Volume
20,940,0942,505,240
Sector
MediaHealth
52-Week High
$51.45$103.98
52-Week Low
$38.40$79.58
Typical Hold Time
109 Days89 Days
Enterprise Value
$379.28B$24.02B
Dividend Yield
6.11%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Verizon Communications Inc

Verizon (VZ) trades at $41.115, down 10.17% over the past day, reflecting recent market pressure. The stock shows a bearish technical signal with key support at $45. Fundamentally, VZ maintains solid profitability with a 59.26% gross margin and has beaten earnings estimates in recent quarters. The company generates strong operating cash flow of $37.14 billion (2025) and offers a consistent dividend, with recent payouts of $0.71 per share. Analyst consensus is a 'Hold' with a $48.17 price target, indicating potential upside from current levels.

The outlook for VZ hinges on execution in the competitive telecom sector. Opportunities include stable cash flow supporting dividends and joint ventures expanding coverage. Risks involve high debt levels, with total debt at $144.01 billion, and pressure from rivals like T-Mobile. Earnings on October 26, 2026, will be critical for confirming growth trends amid economic uncertainties.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.

The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VZ
86% Buy14% Sell
Avg holding period · 109 Days
ZBH
100% Buy0% Sell
Avg holding period · 89 Days

Top news

Latest headlines on both assets

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →